Skip to main content
Quest Diagnostics

Screening for Early Pancreatic Cancer Using Novel LINFU® Ultrasound Technique – Addressing the Unmet Need of Early Screening for Pancreatic Cancer

USCAP 2026

United Steates and Canadian Academy of Pathology   

San Antonio, TX, March 21-26, 2026

Poster presentation: Screening for Early Pancreatic Cancer Using Novel LINFU® Ultrasound Technique – Addressing the Unmet Need of Early Screening for Pancreatic Cancer

Authors: Shah S, Pitman M,  Rutenberg M, Habe Gr, Corbett S, Eisen D, Adam D, Meredith K, Salami A, Bloomston M, Lewis C, Cook T, Perez L, Cupp K,Henderson A, DettloffJ , Varsegi MF, Allam-Nandyala P,  Sarau A, Terrazas T,  Loos JT,  Wheeler DT

Medical Specialty: Oncology

Related Content

Audio Podcast
Exocrine Pancreatic Insufficiency: Symptoms, risk factors, and the value of Pancreatic Elastase testing
Publication
Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors
Audio Podcast
Growing as a Laboratory Partner
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.